{'output': [['Shire', 'COMP', 'Operate_In', 'London', 'GPE'], ['Shire', 'COMP', 'Decrease', '$20 billion', 'ECON_INDICATOR'], ['Shire', 'COMP', 'Introduce', 'two business units', 'CONCEPT'], ['Shire', 'COMP', 'Produce', 'rare disease medicines', 'PRODUCT'], ['Shire', 'COMP', 'Produce', 'ADHD drugs', 'PRODUCT'], ['Shire', 'COMP', 'Has', 'Vyvanse', 'PRODUCT'], ['Shire', 'COMP', 'Relate_To', 'neuroscience business', 'CONCEPT'], ['Shire', 'COMP', 'Positive_Impact_On', 'growth', 'CONCEPT'], ['Shire', 'COMP', 'Positive_Impact_On', 'profitability', 'CONCEPT'], ['Shire', 'COMP', 'Positive_Impact_On', 'innovation', 'CONCEPT'], ['Shire', 'COMP', 'Positive_Impact_On', 'patients needs', 'CONCEPT'], ['Shire', 'COMP', 'Evaluate', 'independent listing', 'CONCEPT'], ['Shire', 'COMP', 'Control', 'hyperactivity drugs', 'PRODUCT'], ['Shire', 'COMP', 'Impact', 'stock value', 'FIN_INSTRUMENT'], ['Analysts', 'CONCEPT', 'Estimate', '$8.5 billion', 'ECON_INDICATOR']]}